Tesamorelin Acetate

CHEMBL2111290 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Tesamorelin acetate is the acetate salt form of tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy. See tesamorelin for complete pharmacological details. This salt formulation is used in approved injectable preparations for subcutaneous administration.

Area Terapeutik

HIV/AIDS

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Tesamorelin acetate is the acetate salt form of tesamorelin, a GHRH analog approved for HIV-associated lipodystrophy. See tesamorelin for complete pharmacological details. This salt formulation is used in approved injectable preparations for subcutaneous administration.

Yes, Tesamorelin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111290. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Tesamorelin Acetate di PillFYI

Data Cepat

Tautan Eksternal

ChEMBL CHEMBL2111290

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.